Antidiabetic Drug Improves Glycemic Control, Insulin Sensitivity

OCTOBER 01, 2004
Susan Farley

A long-term study of the oral antidiabetic drug pioglitazone HCl (Actos) revealed that its use either alone or in combination with other oral antidiabetic medications resulted in sustained improvements in glycemic control, insulin sensitivity, and prominent lipid parameters. Conducted over a 2-year period, the study combined pioglitazone HCl with 2 other common antidiabetic medications: gliclazide and metformin. More than 1200 patients were followed over the 2-year period, and 4 different regimens were evaluated.

The results showed that, regardless of whether pioglitazone HCl was combined with metformin or with gliclazide, there was a significant reduction in fasting insulin, and these decreases were sustained over a period of 2 years. Researchers determined that Actos helps the body use its insulin more efficiently, thereby reducing fasting insulin and reducing demand on the pancreatic beta cells.


Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?

Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.